Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.70 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.52 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935090 | 0.84 | CCR2 (0.67) | CCR2SLC40A1 | |
| SCHEMBL9933923 | 0.83 | CCR2 (1.00) | CCR2PTGES2ACLYSLC40A1 | |
| SCHEMBL9934374 | 0.81 | CCR2 (0.69) | CCR2ACLYSLC40A1 | |
| SCHEMBL28289814 | 0.79 | CCR2 (0.53) | CCR2PTGES2ACLY | |
| SCHEMBL9934413 | 0.78 | CCR2 (1.00) | CCR2PTGES2ACLYSLC40A1 | |
| SCHEMBL9933943 | 0.78 | CCR2 (0.64) | CCR2ALDH1A1 | |
| SCHEMBL9933732 | 0.77 | CCR2 (0.56) | CCR2ALDH1A1 | |
| SCHEMBL9933477 | 0.76 | CCR2 (0.61) | CCR2PTGES2ALDH1A1CCR4 | |
| SCHEMBL9934803 | 0.74 | CCR2 (0.64) | CCR2ALDH1A1 | |
| SCHEMBL27943751 | 0.74 | CCR2 (0.63) | CCR2PTGES2ACLYSLC40A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | claimed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | claimed |
| EP-2651893-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-03-30 | — | — | EP | claimed |
| US-20160083342-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-03-24 | — | — | US | claimed |
| CN-103380115-A | Sulfur derivatives as chemokine receptor modulators | ALLERGAN INC | 2013-10-30 | — | — | CN | claimed |
| EP-2651893-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083342-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885PTGES2 364/4885ACLY 3533/4885 |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885PTGES2 364/4885ACLY 3533/4885 |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885PTGES2 364/4885ACLY 3533/4885 |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885PTGES2 364/4885ACLY 3533/4885 |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | CCR2 3/4885PTGES2 364/4885ACLY 3533/4885 |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | CCR2 3/4885PTGES2 364/4885ACLY 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.